tbuckley/cabot-search huggingface dataset:
P-240 Stage II colon cancer: Epidemiological, clinical characteristics, and therapeutic results. Experience of the medical oncology department of Fez
Authors: Y. Elhaitmy, Z. Benbrahim, S. El Anssari, I. Elbadisy, F. Abbass, L. Amaadour, K. Oualla, S. Arifi, K. Elghazi, M. Nawfel
Journal: Annals of Oncology (2022)
P-108 A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy
Authors: T. Ando, K. Nakashima, H. Yoshita, M. Sakumura, M. Nomura, M. Muto, H. Fujii, Y. Horie, H. Takeda, T. Yoshii, Y. Tahara, C. Katada, K. Yoshimura, H. Ishikawa, A. Hosokawa
Journal: Annals of Oncology (2022)

Both docetaxel and paclitaxel are a class of microtubule-stabilizing anticancer agents. Partial cross-resistance between docetaxel and paclitaxel was indicated in breast and ovary cancers. In advanced gastric cancer, retrospective study showed comparable efficacy of subsequent weekly paclitaxel with or without prior docetaxel-based chemotherapy. Therefore, we evaluated the efficacy and safety of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy. This study was a multi-center, single-arm phase II study in patients with advanced or recurrent esophageal cancer. Eligible criteria included histologically confirmed esophageal squamous cell carcinoma or adenosquamous carcinoma with measurable lesions, refractory to prior docetaxel-containing chemotherapy, aged 20 years and older, and an ECOG performance status (PS) of 0-1. Paclitaxel at 100 mg/m2 was administered by intravenous infusion, and this was repeated weekly for 6 weeks followed by a 1-week rest. The primary end point was confirmed objective response rate (ORR), as assessed according to the RECIST version 1.1 criteria. The secondary end points included progression-free survival (PFS), overall survival (OS) and safety. Between January 2016 and November 2019, 25 patients were enrolled from 6 institutions in Japan. Two patients with ineligible (n=1) and refusal of treatment (n=1) were excluded. Therefore, 23 patients were included in this analysis. In prior treatment, all patients received fluoropyrimidine, platinum and docetaxel. The median number of treatment cycles was 2 (range 1–4). The ORR was 9% (2/23), however, the confirmed ORR was 0%. The disease control rates (DCR) was 52% (12 /23). The median PFS and median OS were 81 days (95% confidence intervals (CI), 47 to 91), and 211 days (95% CI, 162 to 262), respectively. The common grade 3 or 4 treatment-related adverse events were neutropenia (34%), leukocytopenia (26%) and anemia (22%). There were no treatment-related deaths. Although this phase II study did not meet the primary endpoint, it showed modest efficacy with an acceptable safety profile.
P-159 Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04): A randomized phase 3 study
Authors: K. Shitara, F. Barlaskar, F. Franke, Y. Kawaguchi, L. Shen, T. Kamio, G. Meinhardt, J. Tabernero
Journal: Annals of Oncology (2022)
Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes
Authors: Lisa J. McReynolds, Maryam Rafati, Youjin Wang, Bari J. Ballew, Jung Kim, Valencia V. Williams, Weiyin Zhou, Rachel M. Hendricks, Casey Dagnall, Neal D. Freedman, Brian Carter, Sara Strollo, Belynda Hicks, Bin Zhu, Kristine Jones, Sophie Paczesny, Steven G. E. Marsh, Stephen R. Spellman, Meilun He, Tao Wang, Stephanie J. Lee, Sharon A. Savage, Shahinaz M. Gadalla
Journal: Blood (2022)
Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial
Authors: Philip A.J. Crosbie, Rhian Gabe, Irene Simmonds, Neil Hancock, Panos Alexandris, Martyn Kennedy, Suzanne Rogerson, David Baldwin, Richard Booton, Claire Bradley, Mike Darby, Claire Eckert, Kevin N. Franks, Jason Lindop, Sam M. Janes, Henrik Møller, Rachael L. Murray, Richard D. Neal, Samantha L. Quaife, Sara Upperton, Bethany Shinkins, Puvan Tharmanathan, Matthew E.J. Callister
Journal: European Respiratory Journal (2022)

Screening with low-dose computed tomography (LDCT) reduces lung cancer mortality; however, the most effective strategy for optimising participation is unknown. Here we present data from the Yorkshire Lung Screening Trial, including response to invitation, screening eligibility and uptake of community-based LDCT screening.
P-284 Genes associated with angiogenesis may be regulated by metabolic radiotherapy on cholangiocarcinoma cells
Authors: R. Ferreira, M. Calastri, P. Jordão, G. Tenani, L. Spinola, S. Júnior, R. da Silva, R. da Silva, A. Abrantes, M. Botelho, A. de Brito, J. Tralhão, I. Boin, D. Souza
Journal: Annals of Oncology (2022)
The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programme
Authors: Christer Janson, Ekaterina Maslova, Alexander Wilkinson, Erika Penz, Alberto Papi, Nigel Budgen, Claus F. Vogelmeier, Maciej Kupczyk, John Bell, Andrew Menzies-Gow
Journal: European Respiratory Journal (2022)

Climate change represents a global challenge and nations are increasingly looking to decarbonise their economies by developing roadmaps for reducing greenhouse gas (GHG) emissions in accordance with international treaties, such as the Paris Agreement [1]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Christer Janson reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline PLC, Novartis and Teva outside the submitted work. Conflict of interest: Alexander Wilkinson is a member of the Montreal protocol Medical and Chemical Technical Options Committee and has made unpaid contributions to publications on the carbon footprint of inhalers and respiratory treatment which were sponsored by GlaxoSmithKline and AstraZeneca. Conflict of interest: Erika Penz has received honoraria and consulting fees from AstraZeneca, GlaxoSmithKline, Sanofi Genzyme, International Centre for Evidence-Based Medicine in Canada and Boehringer Ingelheim. Conflict of interest: Alberto Papi reports grants and personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Menarini and Sanofi/Regeneron; personal fees from Mundipharma, Zambon, Novartis, Edmond Pharma and Roche; and grants from Fondazione Maugeri and Fondazione Chiesi. Conflict of interest: Claus F. Vogelmeier has delivered presentations at symposia and/or served on scientific advisory boards sponsored by Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Grifols, Menarini, Novartis, Nuvaira and MedUpdate. Conflict of interest: Maciej Kupczyk reports grants from AstraZeneca and personal fees from AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, Lekam, Alvogen, Emma, Nexter and Berlin Chemie. Conflict of interest: Ekaterina Maslova, Nigel Budgen and John Bell are employees of AstraZeneca. Conflict of interest: Andrew Menzies-Gow has attended advisory boards for GlaxoSmithKline, Novartis, AstraZeneca, Sanofi and Teva. He has received speaker fees from Novartis, AstraZeneca, Vectura, Teva and Roche. He has also participated in research with AstraZeneca and attended international conferences with Teva. He has consultancy agreements with AstraZeneca, Vectura and Sanofi.
How doctors manage conflicts with families of critically ill patients during conversations about end-of-life decisions in neonatal, pediatric, and adult intensive care
Authors: Amber S. Spijkers, Aranka Akkermans, Ellen M. A. Smets, Marcus J. Schultz, Thomas G. V. Cherpanath, Job B. M. van Woensel, Marc van Heerde, Anton H. van Kaam, Moniek van de Loo, Dick L. Willems, Mirjam A. de Vos
Journal: Intensive Care Medicine (2022)

Intensive care is a stressful environment in which team-family conflicts commonly occur. If managed poorly, conflicts can have negative effects on all parties involved. Previous studies mainly investigated these conflicts and their management in a retrospective way. This study aimed to prospectively explore team-family conflicts, including its main topics, complicating factors, doctors’ conflict management strategies and the effect of these strategies. Conversations between doctors in the neonatal, pediatric, and adult intensive care unit of a large university-based hospital and families of critically ill patients were audio-recorded from the moment doubts arose whether treatment was still in patients’ best interest. Transcripts were coded and analyzed using a qualitative deductive approach. Team-family conflicts occurred in 29 out of 101 conversations (29%) concerning 20 out of 36 patients (56%). Conflicts mostly concerned more than one topic. We identified four complicating context- and/or family-related factors: diagnostic and prognostic uncertainty, families’ strong negative emotions, limited health literacy, and burden of responsibility. Doctors used four overarching strategies to manage conflicts, namely content-oriented, process-oriented, moral and empathic strategies. Doctors mostly used content-oriented strategies, independent of the intensive care setting. They were able to effectively address conflicts in most conversations. Yet, if they did not acknowledge families’ cues indicating the existence of one or more complicating factors, conflicts were likely to linger on during the conversation. This study underlines the importance of doctors tailoring their communication strategies to the concrete conflict topic(s) and to the context- and family-related factors which complicate a specific conflict.
Familiarity with the post-intensive care syndrome among general practitioners and opportunities to improve their involvement in ICU follow-up care
Authors: Johan H. Vlake, Evert-Jan Wils, Jasper van Bommel, Diederik Gommers, Michel E. van Genderen, Tim I. M. Korevaar, Paul W. J. Vlake, Matilde Hobers
Journal: Intensive Care Medicine (2022)
Metastatic Giant Cell Tumor Causing Small Bowel Intussusception on 18F-FDG PET/CT
Authors: Julie E. Walcutt, Craig M. Johnson, Quan P. Ly, Ryan T. Downey
Journal: Clinical Nuclear Medicine (2022)

An 89-year-old man with a history of a malignant giant cell tumor of soft parts in the right thigh with recurrent/metastatic tumor in the right pelvis was found to have pulmonary nodules concerning for metastatic disease. Subsequent PET/CT unexpectedly demonstrated a right lower quadrant intussusception with a hypermetabolic mass serving as a lead point. Pathology of the resected mass causing the intussusception was compatible with a metastasis from the patient's malignant giant cell tumor of soft parts.
P-69 Anal squamous cell carcinoma (ASCC) outcomes in clinical practice: From localized to metastatic setting
Authors: J. Esteban Villarrubia, J. Hernando, P. Gómez Mugarza, A. García Álvarez, J. Torres Jiménez, I. Orejana Martín, V. Alonso Orduña, D. Gómez-Puerto, P. Álvarez Ballesteros, E. Polo, D. López, Í. Martínez Delfrade, B. López Roldán, M. Roca, P. Reguera Puertas, S. Barriendos Sanz, L. Benini, R. Ferreiro Monteagudo, M. Monreal Cepero, S. Campos Ramírez, C. Guillén-Ponce, J. Capdevila
Journal: Annals of Oncology (2022)
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
Authors: Kai Rejeski, Zhijie Wu, Viktoria Blumenberg, Wolfgang G. Kunz, Susanna Müller, Sachiko Kajigaya, Shouguo Gao, Veit L. Bücklein, Lisa Frölich, Christian Schmidt, Michael von Bergwelt-Baildon, Xingmin Feng, Neal S. Young, Marion Subklewe
Journal: Blood (2022)

The advent of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of refractory B-cell malignancies. Real-world evidence has highlighted the high incidence of hematological toxicity, including prolonged and profound cytopenia. Here, we present a case of bone marrow (BM) failure in a 57-year old man with DLBCL-type Richter transformation receiving tisagenlecleucel in a standard-of-care setting. His clinical course was notable for underlying BM infiltration, severe cytokine release syndrome, and multiple infectious complications in the setting of prolonged, profound neutropenia. Cytokine profiling revealed a signature consistent with acquired aplastic anemia - including downregulation of CD40-L and EGF. Flow cytometric analyses demonstrated migration of CAR T-cells to the BM, as well as peripheral blood expansion of both CAR and non-CAR bearing CD8+CD57+ T-cells, an immunophenotype linked to oligoclonality in aplastic anemia. From single-cell level transcriptomics, this cytotoxic T-cell population was characterized by T-cell receptor Vβ oligoclonal expansion and post-CAR clonal drift. Gene expression profiling revealed upregulation of exhaustion markers on (CAR) T-cells and decreased expression of genes involved in STAT signalling and inflammatory response. In conclusion, this case highlights the complex nature of CAR-T-related hematological toxicity and introduces oligoclonal (CAR) T-cell expansion as a potential contributing pathophysiologic mechanism.
P-78 A phase II study of resection followed by capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Final analysis
Authors: H. Tamagawa, N. Sugimoto, T. Watanabe, H. Satake, K. Kataoka, K. Kamei, M. Kobayashi, K. Munakata, M. Fukunaga, M. Kotaka, T. Satoh, A. Kanazawa, T. Kurata, N. Tomita
Journal: Annals of Oncology (2022)
Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis
Authors: Samir V. Parikh, Ana Malvar, Huijuan Song, John Shapiro, Juan Manuel Mejia-Vilet, Isabelle Ayoub, Salem Almaani, Sethu Madhavan, Valeria Alberton, Celeste Besso, Bruno Lococo, Anjali Satoskar, Jianying Zhang, Lianbo Yu, Paolo Fadda, Michael Eadon, Dan Birmingham, Latha P. Ganesan, Wael Jarjour, Brad H. Rovin
Journal: Kidney International (2022)
P-291 PIK3CA mutations in Tunisian patients with metastatic colorectal cancer: Patient stratification for targeted therapies
Authors: A. Jaballah-Gabteni, H. Guettiti Tounsi, I. Ben Ayed, H. Yaïche, N. Ben Jemii, D. Wider, S. Boubaker
Journal: Annals of Oncology (2022)
68Ga-FAPI-46 PET/CT in a Metastatic Castration-Resistant Prostate Cancer Patient With Low PSMA Expression
Authors: Kamran Aryana, Reyhaneh Manafi-Farid, Hamidreza Amini, Ghasemali Divband, Soroush Zarehparvar Moghadam
Journal: Clinical Nuclear Medicine (2022)

A 70-year-old man with mCRPC (metastatic castration-resistant prostate cancer) was referred for 68 Ga-PSMA PET/CT for restaging and the possibility of targeted molecular radioligand therapy with 177 Lu-PSMA. Numerous 68 Ga-PSMA-avid skeletal metastases with low SUVs were noted. Because of low PSMA expression, a 68 Ga-FAPI-46 PET/CT was performed to evaluate the eligibility for FAPI-based radioligand therapy. There were some discordant findings between 68 Ga-PSMA and 68 Ga-FAPI PET/CT scans regarding the detectability of lesions and SUVs. Our case signifies that 68 Ga-FAPI theragnostic may have a potential role in the treatment of mCRPC patients with insignificant PSMA expression or in cases after the failure of 177 Lu-PSMA therapy.
SO-36 An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study
Authors: C. Antoniotti, A. Boccaccino, R. Seitz, M. Giordano, D. Rossini, M. Ambrosini, L. Salvatore, K. McGregor, F. Bergamo, V. Conca, S. Leonetti, L. Provenzano, S. Tamberi, M. Ramundo, G. Tortora, C. Rasola, D. Ross, A. Passardi, T. Nielsen, M. Varga, C. Cremolini
Journal: Annals of Oncology (2022)
Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
Authors: Guido Antonelli, Daniele Focosi, Ombretta Turriziani, Marco Tuccori, Rossella Brandi, Silvia Fillo, Camilla Ajassa, Florigio Lista, Claudio M. Mastroianni
Journal: Clinical Microbiology and Infection (2022)
Reply: The new ERS/ATS standards on lung function test interpretation: some extant limitations
Authors: Sanja Stanojevic, David A. Kaminsky, Martin Miller, Bruce Thompson
Journal: European Respiratory Journal (2022)

<b>The updated technical statement on pulmonary function test interpretation focuses on physiological interpretation. There are important considerations regarding how these updated standards can be incorporated into clinical practice.</b> https://bit.ly/3xDZGOJ
Biliary stent placement with modified Shim technique in a child with tracheoesophageal fistula and esophageal stricture
Authors: Joel Ferreira-Silva, Eduardo Rodrigues-Pinto, Filipe Vilas-Boas, Guilherme Macedo
Journal: Endoscopy (2022)

A 2-year-old boy was admitted as an emergency because of ingestion of a button battery. Upper endoscopy revealed a foreign body and circumferential mucosal necrosis at the proximal esophagus. The battery was removed using foreign-body forceps, and esophagography 1 week later showed no complications.
O-3 Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648
Authors: I. Chau, J. Ajani, Y. Doki, J. Xu, L. Wyrwicz, S. Motoyama, T. Ogata, H. Kawakami, C. Hsu, A. Adenis, F. El Hajbi, M. Di Bartolomeo, M. Braghiroli, E. Holtved, M. Blum Murphy, S. Abdullaev, S. Soleymani, M. Lei, K. Kato, Y. Kitagawa
Journal: Annals of Oncology (2022)

NIVO + chemo and NIVO + IPI demonstrated significant overall survival (OS) benefit vs chemo in previously untreated patients with advanced ESCC in the phase 3 CheckMate 648 study. We report expanded results from the primary analysis, including factors associated with the timing of the onset of treatment effect. Patients with previously untreated, unresectable advanced, recurrent, or metastatic ESCC were randomized to NIVO (240 mg Q2W) + chemo (fluorouracil + cisplatin Q4W), NIVO (3 mg/kg Q2W) + IPI (1 mg/kg Q6W), or chemo. Primary endpoints were OS and progression-free survival (PFS) per blinded independent central review (BICR) in patients with tumor cell programmed death ligand 1 (PD-L1) ≥ 1%. Secondary endpoints planned for hierarchical testing included OS, PFS, and objective response rate (ORR) per BICR in all randomized patients. Duration of response (DOR) per BICR and PFS2 (time from randomization to progression after subsequent systemic therapy, initiation of second subsequent systemic therapy, or death) per investigator were exploratory endpoints. Among all patients randomized to NIVO + chemo (n = 321), NIVO + IPI (n = 325), or chemo (n = 324), PFS2 favored NIVO + chemo (HR 0.64, 95% CI 0.54–0.77) and NIVO + IPI (HR 0.74, 95% CI 0.62–0.88) vs chemo at 13-month minimum follow-up. ORR (95% CI) was 47% (42–53) with NIVO + chemo, 28% (23–33) with NIVO + IPI, and 27% (22–32) with chemo. More responders with NIVO + chemo or NIVO + IPI vs chemo had prolonged DOR (≥12 months; 39%, 48%, and 23%, respectively). Piecewise HRs of overall survival between treatment arms and factors associated with delayed onset of effect of NIVO + IPI relative to chemo-based regimens will be presented. The majority of treatment-related adverse events with potential immunologic etiology (select TRAEs) were grade 1 or 2, and grade 3/4 events occurred in ≤ 6% of patients with NIVO + chemo and NIVO + IPI. Select TRAEs of any grade occurred within a median of 5 to 31 weeks with NIVO + chemo and 4 to 12 weeks with NIVO + IPI across organ categories. Nonendocrine select TRAEs resolved in most patients in the NIVO + chemo (57% to 91%) and NIVO + IPI (63% to 95%) groups across organ categories with the use of established management algorithms (median time to resolution, 2 to 17 weeks and 3 to 12 weeks, respectively). NIVO + chemo and NIVO + IPI demonstrated favorable PFS2 and a higher proportion of patients with prolonged DOR vs chemo, along with acceptable safety profiles. These results provide further support for each regimen as a new potential first-line standard therapy in advanced ESCC.
Primary Hepatic Angiosarcoma Having FDG Uptake at the Similar Level of the Normal Liver Parenchyma
Authors: Peipei Wang, Fang Li
Journal: Clinical Nuclear Medicine (2022)

Primary hepatic angiosarcoma is a rare but aggressive malignancy. A 60-year-old woman presented with multiple liver lesions with progressive enhancement detected with multiphasic CT. FDG PET did not show any FDG-avid lesions, and the uptake of hepatic lesions was similar to that of the normal liver parenchyma. Subsequently, pathological examination revealed hepatic angiosarcoma.
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
Authors: Liza Chacko, Nina Karia, Lucia Venneri, Francesco Bandera, Beatrice Dal Passo, Lodovico Buonamici, Jonathan Lazari, Adam Ioannou, Aldostefano Porcari, Rishi Patel, Yousuf Razvi, James Brown, Daniel Knight, Ana Martinez‐Naharro, Carol Whelan, Candida C. Quarta, Charlotte Manisty, James Moon, Dorota Rowczenio, Janet A. Gilbertson, Helen Lachmann, Ashutosh Wechelakar, Aviva Petrie, William E. Moody, Richard P. Steeds, Luciano Potena, Mattia Riefolo, Ornella Leone, Claudio Rapezzi, Philip N. Hawkins, Julian D. Gillmore, Marianna Fontana
Journal: European Journal of Heart Failure (2022)
Incorporating Cultural Competence and Cultural Humility in Cardiovascular Clinical Trials to Increase Diversity Among Participants
Authors: Jie Wei Zhu, Francesca D'Angelo, J. Jaime Miranda, Clyde W. Yancy, Blanche Cupido, Faiez Zannad, Harriette G.C. Van Spall
Journal: Journal of the American College of Cardiology (2022)
Soil and water pollution and human health: what should cardiologists worry about?
Authors: Thomas Münzel, Omar Hahad, Andreas Daiber, Philip J Landrigan
Journal: Cardiovascular Research (2022)

Healthy soil is foundational to human health. Healthy soil is needed to grow crops, provides food, and sustains populations. It supports diverse ecosystems and critical ecological services such as pollination. It stores water and prevents floods. It captures carbon and slows global climate change. Soil pollution is a great and growing threat to human health. Soil may be polluted by heavy metals, organic chemicals such as pesticides, biological pathogens, and micro/nanoplastic particles. Pollution reduces soil's ability to yield food. It results in food crop contamination and disease. Soil pollutants wash into rivers causing water pollution. Deforestation causes soil erosion, liberates sequestered pollutants, and generates airborne dust. Pollution of air, water, and soil is responsible for at least 9 million deaths each year. More than 60% of pollution-related disease and death is due to cardiovascular disease. Recognizing the importance of pollution to human health, the European Commission and the EU Action Plan for 2050: A Healthy Planet for All, have determined that air, water, and soil pollution must be reduced to levels that cause no harm to human or ecosystem health. We are thus required to create a toxic-free environment, respect the concept of a safe operating space for humanity, and sustain the health of our planet for future generations. This review article summarizes current knowledge of the links between soil health and human health and discusses the more important soil pollutants and their health effects.